Investors in Lexington, Massachusetts-based Agenus (AGEN) had a very good day on Tuesday. The immune-oncology biotech specialist announced a deal to license its anti-TIGIT (a.k.a. T cell immunoreceptor with Ig and ITIM domains) bispecific antibody program to Bristol Myers Squibb (BMY). As a result, investors bid Agenus stock up more than 20% in the following trading sessions. It's easy to see why they were excited. From Bristol Myers' perspective, it will gain an exclusive global license to use Agenus's proprietary bispecific antibody program, AGEN1777, "that blocks TIGIT and a second undisclosed target," with the aim of improving a body's ability to destroy cancerous tumors -- in particular, non-small cell lung cancer.
https://www.tipranks.com/news/article/is-agenus-stock-still-worth-buying-after-its-20-plus-rally-analyst-weighs-in
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Sep 2021 to Oct 2021 Click Here for more Agenus Charts.
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Oct 2020 to Oct 2021 Click Here for more Agenus Charts.